The FDA is currently reviewing a groundbreaking mRNA flu vaccine developed by Moderna marking a significant milestone in vaccine technology. This innovative shot, named mFlusiva is the first of its kind to utilize the same mRNA technology that played a crucial role in combating the COVID-19 pandemic.
On June 18, 2026 the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened to discuss the potential approval of mFlusiva for adults aged 50 and older. This meeting is a critical step toward making the vaccine available ahead of the upcoming winter flu season.
Moderna’s mRNA Vaccine: A Potential Game-Changer
The mRNA technology used in Moderna’s vaccine offers several advantages over traditional flu vaccines. One of the most significant benefits is the speed at which these vaccines can be manufactured. This rapid production capability is particularly important given the flu virus’s ability to mutate quickly, requiring timely updates to vaccine formulations.
In a comprehensive study involving nearly 40,000 participants aged 50 and older, Moderna’s mRNA vaccine demonstrated a 27% reduction in flu cases compared to a commonly used standard-dose vaccine. The FDA’s preliminary review of this data did not raise any safety concerns, paving the way for further consideration.
The Path to Approval: Challenges and Considerations
The journey to approval for Moderna’s mRNA flu vaccine has not been without its challenges. Earlier in 2026, the FDA initially blocked the company’s application, citing concerns about the study’s design. Dr. Vinay Prasad then a top FDA official, argued that the vaccine should have been compared to a high-dose flu vaccine recommended for seniors rather than a standard-dose brand. This decision sparked a public dispute, highlighting the heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr..
Moderna responded by emphasizing that the FDA had initially approved the study’s design and pointed to a smaller study that compared the mRNA shot with a high-dose vaccine for seniors. Days after the initial rejection, the FDA accepted Moderna’s revised application, allowing the review process to proceed.
Addressing Concerns and Gathering Data
The expert panel is also assessing a smaller study that found Moderna’s mRNA vaccine generated flu-fighting antibodies similarly to a high-dose senior shot. However, the FDA’s initial review noted that the new vaccine lacks data on very frail older adults and those with weak immune systems. This gap in data is a critical consideration for the panel as they evaluate the vaccine’s
Moderna is seeking full approval for the vaccine’s use in the 50- to 64-year-old population along with authorization for use in those 65 and older while additional testing is conducted. This bifurcated approach aims to address the FDA’s concerns while expediting the availability of the vaccine for those who need it most.
The Future of Flu Prevention
The potential approval of Moderna’s mRNA flu vaccine represents a significant step forward in the fight against influenza. With tens of thousands of Americans dying from the flu each year, the need for effective and adaptable vaccines is more critical than ever. The mRNA technology offers a promising solution, providing a faster and more flexible approach to vaccine development.
As the FDA continues its review, the outcome of the VRBPAC meeting will be closely watched by health experts and the public alike. The decision could set a precedent for the future of vaccine development, paving the way for more innovative and effective solutions to combat infectious diseases.
